Supported by in-house scientists and a first-in-class technological platform, Creative Biolabs has expanded our service capabilities to offer fully integrated B cell engineering service for anti-glioma antibody delivery to best suit the client's program requirements.
Glioblastoma (GBM) is a common and aggressive malignant tumor of the central nervous system (CNS), characterized by complex molecular heterogeneity and invasive growth. Although trials of novel drugs have been going on for decades, the median survival of patients has remained unchanged at 14~17 months. In recent years, many researchers have focused on the GBM immunity cycle, which has generated many new targeted therapy options.
Fig.1 The GBM immunity cycle and
associated targeted therapy options. (Bausart, et al., 2022)
Leveraging our expertise and experience, Creative Biolabs is committed to providing B cell engineering services for anti-glioma antibody delivery to accelerate glioma antibody research. We are proud to offer integrated research portfolio services for global customers to meet your research needs. The following is our workflow for our one-stop B cell engineering service. Every step of our operation will have strict quality control, from cell isolation to final verification.
Fig.2 The main workflow for the one-stop B
cell engineering service. (Creative Biolabs)
| Targeting Neoantigen | GD2; IL13Rα2; HER2; EphA2; Survivin; TRP2; WT1; gp100; SOX2; SOX11; MAGE-A1; AIM2; EGFRvIII; Chlorotoxin; CD70; CD133...... |
| Targeting TME | PD-1; PD-L1; IDO; CD47; CD40; CXCR4; CD73...... |
Creative Biolabs is committed to providing high-quality, efficient, and integrative study assay portfolio services to help our clients shorten their research journey.
For more detailed information on B cell engineering service for anti-glioma antibody delivery, please feel free to contact us or directly sent us an inquiry.